Alpha Therapeutic Names Edward A. Colton President And CEO; Additions to Senior Management Announced as Company Addresses Operational Issues.

Business Editors & Health/Medical Writers

BIOWIRE2K

LOS ANGELES--(BW HealthWire)--Oct. 2, 2000

Edward A. Colton was promoted to president and chief executive officer of Alpha Therapeutic Corp., the company announced today.

Colton, a 19-year veteran of the company, was most recently chief operating officer. He joined Alpha in 1981 as general counsel and director, Corporate Taxes and was previously senior vice president, general counsel and chief financial officer.

As president and CEO, and a member of Alpha's board of directors, Colton is responsible for leading the company as it emerges from operational and compliance issues that have affected its plasma fractionation operations.

"We are focused on resuming operations and once again providing our life-saving therapies to patients in need," said Colton. "I am confident that our on-going investments in facilities and systems have demonstrated our commitment and that 2001 will be a turning point in Alpha's history."

Key additions to Alpha's senior management team were also announced. Claude Miller has joined the company as vice president, Quality Assurance. Miller was most recently senior director, Operations at SangStat Medical Corp. He has extensive experience in the quality and regulatory fields at several biotechnology and medical products companies. Miller received a bachelor's degree and a master's degree in molecular biology/microbiology from California State University, Long Beach.

David Bell has joined Alpha as vice president and general counsel from the law firm of Knapp, Petersen and Clark and has represented Alpha on various legal issues for 18 years. Bell graduated from the University of California, Irvine with a major in psychobiology and began graduate work in neuropharmacology before entering law school. He graduated from Southwestern University School of Law, was admitted to practice law in California in 1979 and has focused his practice on complex matters involving health care, pharmaceutical and biotechnology regulation and liability.

Alpha is a leading developer of plasma derived biopharmaceutical products including coagulation factors, immune globulin and albumin. With headquarters in Los Angeles, Alpha is committed to providing high quality, safe and cost-effective therapeutics for improved patient care worldwide. Additional company information is available at www.alphather.com.